MAPT and Alzheimer disease: In AD, an enhancement in the ethanolamine-containing plasmalogens and platelet activating factor (PAF) precursors hydrolysis results in accumulation of PlsEtns and PAF metabolism products [i.e., PC(O-16:0/2:0) and PE(P-16:0/0:0)], which accelerates tau pathology, enhances vesicular release, and signals neuronal loss [122].